Our results also suggest that, in order to reverse tumor-associated immunosuppression mediated by myeloid cells, strategies based on the inhibition of M-CSF-R should be privileged to prevent the effects of both IL-34 and M-CSF. This evidence concerns the gene IL34 and neoplasm.